| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Posard Matthew L. is a Director at HALOZYME THERAPEUTICS, INC. with holdings across 2 companies. Recent SEC Form 4 filings include 4 buys and 8 sells.
Estimated insider holdings value: $5.4M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 14, 2024 | HALO Halozyme Therapeutics, Inc. | Director | Sell | 29,881 | $56.53 | $1,689,293.70 | -11.1% | +3.8% | +14.2% | |
| Jun 12, 2024 | HALO Halozyme Therapeutics, Inc. | Director | Sell | 20,000 | $50.32 | $1,006,300.00 | -8.7% | +19.3% | +9.8% | |
| Dec 6, 2022 | HALO Halozyme Therapeutics, Inc. | Director | Sell | 30,000 | $56.89 | $1,706,550.00 | -8.0% | -19.3% | -29.1% | |
| Dec 1, 2021 | NAUT Nautilus Biotechnology, Inc. | Director | Buy | 50,000 | $4.51 | $225,505.00 | +55.6% | -12.1% | -59.1% |